| http://www.w3.org/ns/prov#value | - BEVERLY, MA., Octoberber 22, 2012???Cellceutix Corporation (OTCBB: CTIX) (the ???Company???), a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, announces an update on the status of clinical trials for the Company???s novel anti-cancer drug candidate, Kevetrin???.
|
